Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection. Oramed has an experienced management team with many years of business and pharmaceutical experience, and is backed by world-class scientific experts. From the companyâs inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog (exenatide) capsule, ORMD-0901. Source
No articles found.
VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company...
VistaGen Therapeutics (NASDAQ: VTGN) is a clini...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Amarantus BioSciences is a development-stage, publicly-traded biotechnology compan...
Amarantus BioSciences is a development-stage, p...
Proteon Therapeutics is working to deliver a new future for patients and families ...
Proteon Therapeutics is working to deliver a ne...
Join the National Investor Network and get the latest information with your interests in mind.